



CONSEGNA
DELIVERING INNOVATION

CONSEGNA RAISES \$1 MILLION VIA PRIVATE PLACEMENT

Highlights:

- Private placement to sophisticated and professional investors
- Funds to accelerate the Turbine Launch in Australia later this calendar year, and drive the sleep and drug delivery programs

Melbourne, Australia – 21 August 2013

Medical technology Company Consegna Group (ASX: CGP) is pleased to announce it has successfully completed a private placement with professional and sophisticated investors through Peloton Capital raising approximately A\$1,000,000 before costs.

The placement of 25,000,000 new fully paid ordinary shares at an issue price of A\$0.04 per share represents a 5% discount to the last traded ordinary share price in the company as at the date of this announcement. The placement does not require shareholder approval, as it comprises the remaining balance of the Company's capacity under Listing Rules 7.1 and 7.1A.

Consegna Chairman Martin Rogers said, "This private placement received strong support from the investment community and was oversubscribed. It shows the confidence investors have in the turn around that has taken place and is a reflection of the renewed investor interest in quality medical technology companies that have strong near term revenue opportunities."

Consegna Chief Executive Officer Mr Michael Johnson added, "This fund raising enables the Company to accelerate the launch of the Turbine into the online sport and exercise market later this year. Additionally, we are now well placed to progress the development of our sleep and drug delivery programs. We thank the Placement's sole Lead Manager, Peloton Capital for their guidance and support in the rapid close of this raising".

In addition, and subject to shareholder approval at the Company's 2013 Annual General Meeting, the Company will issue one free attaching option for each four shares subscribed for under the placement. The options will have an exercise price of \$0.06 (6 cents) and an expiry date of 30 April 2017. The Company will apply to the ASX for official quotation of attaching options.

An Appendix 3B and information required by ASX Listing Rule 3.10.5A will be lodged with ASX upon the issue and allotment of the placement shares. None of the subscribers for shares in the placement are related parties of the Company or associates of related parties.

Media Enquiries

Michael Johnson, CEO & Executive Director
+61 (03) 9614 3663
mjohnson@consegna.com



For personal use only



About Consegna Group Limited (ASX:CGP)

Consegna is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise application of its BreatheAssist technology portfolio in the Sport, Snoring, Olfactory, Sleep and Drug Delivery markets. For more information go to www.consegna.com

About the Turbine™

The Turbine is a revolutionary product, which utilises the BreatheAssist technology and can deliver to athletes on average 38% increase in airflow through the nasal passages. In a recent athlete user trial, two thirds of respondents reported that when using a Turbine™ prototype they felt they got more air into their lungs and 60% reported that they felt less fatigued during training.

The Turbine product range has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training.

For personal use only